Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04382586
Recruitment Status : Completed
First Posted : May 11, 2020
Last Update Posted : June 16, 2021
Sponsor:
Information provided by (Responsible Party):
BeiGene

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary objective of this study is to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019 (COVID-19) and pulmonary distress.

Condition or disease Intervention/treatment Phase
COVID-19 Pulmonary Complications COVID-19 Drug: Zanubrutinib Drug: Supportive Care Drug: Placebo Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 67 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress
Actual Study Start Date : July 6, 2020
Actual Primary Completion Date : February 1, 2021
Actual Study Completion Date : February 1, 2021

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Cohort 1: Zanubrutinib + Supportive Care
Participants not requiring mechanical ventilation (Cohort 1) will receive zanubrutinib plus supportive care
 Drug: Zanubrutinib
320 mg (4 x 80 mg) capsules administered orally once daily.
Other Names:
  • BGB-3111
  • Brukinsa

Drug: Supportive Care
Supportive care treatment is selected and administered as deemed appropriate by the study investigator.
Active Comparator: Cohort 1: Placebo + Supportive Care
Participants not requiring mechanical ventilation (Cohort 1) will receive placebo plus supportive care alone
 Drug: Supportive Care
Supportive care treatment is selected and administered as deemed appropriate by the study investigator.

Drug: Placebo
Placebo to match zanubrutinib
Experimental: Cohort 2: Zanubrutinib+Supportive Care
Participants who have been on mechanical ventilation for ≤ 24 hours (Cohort 2) will receive zanubrutinib plus supportive care alone for respiratory distress due to COVID-19 infection for up to 28 days
 Drug: Zanubrutinib
320 mg (4 x 80 mg) capsules administered orally once daily.
Other Names:
  • BGB-3111
  • Brukinsa

Drug: Supportive Care
Supportive care treatment is selected and administered as deemed appropriate by the study investigator.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Respiratory failure-free survival rate at day 28 [ Time Frame: 28 Days ]
    Respiratory failure-free survival rate 28 is defined as the proportion of patients who have not had respiratory failure nor died <= 28 days from randomization.


Secondary Outcome Measures :
  1. Median reduction in days spent on supplemental oxygen [ Time Frame: Up to 28 Days ]
  2. All-cause mortality [ Time Frame: Up to 28 Days ]
  3. Proportion of participants experiencing respiratory failure or death [ Time Frame: Up to 28 Days ]
  4. Mechanical ventilation-free survival [ Time Frame: Up to 28 Days ]
  5. Days on mechanical ventilation [ Time Frame: Up to 28 Days ]
  6. Duration of hospitalization [ Time Frame: Up to 28 Days ]
  7. Time to discharge [ Time Frame: Up to 28 Days ]
  8. PaO2:FiO2 and/or oxygenation index [ Time Frame: Up to 28 Days ]
  9. Change from Baseline to Day 14 in WHO - 8 Point Ordinal Scale [ Time Frame: Up to 28 Days ]
    This scale evaluates the safety and efficacy of investigational therapeutic agents in combination with care for the treatment of hospitalized participants suffering from COVID-19 infections on a scale of scores from 0 to 8, with higher scores indicating higher level of severity of the disease. (0 = No clinical or virological evidence of disease, and 8 = Death)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Hospitalization for COVID-19 infection
  2. Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by polymerase chain reaction (PCR)
  3. Cohort 1: Participant requires supplemental oxygen for pulmonary distress related to COVID-19 infection, and has been on supplemental oxygen for no more than 48 hours. Cohort 2: Participants will have been on mechanical ventilation for ≤ 24 hours from the time of screening
  4. Radiographic evidence of pulmonary infiltrates

Key Exclusion Criteria:

  1. Participant is on mechanical ventilation for > 24 hours
  2. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction
  3. On a BTK inhibitor
  4. Planned or concurrent use of tocilizumab
  5. Participants with cancer

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04382586


Locations
Show Show 18 study locations
Sponsors and Collaborators
BeiGene
Investigators
Layout table for investigator information
Study Director: Todd Zimmerman, MD BeiGene
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: BeiGene
ClinicalTrials.gov Identifier: NCT04382586    
Other Study ID Numbers: BGB-3111-219
First Posted: May 11, 2020    Key Record Dates
Last Update Posted: June 16, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by BeiGene:
Corona Virus
COVID-19
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Infections
Respiratory Tract Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
 RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Zanubrutinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action